By defining four molecular subtypes and integrating key prognostic biomarkers—such as POLE mutations, mismatch repair deficiency, and p53 abnormalities—this framework enables more accurate risk stratification and precision-guided therapy. Here, TP53 is linked to mismatch repair cancer syndrome 1.